Valneva SE - חוב לטווח קצר של החברה VALN

Valneva SE (VALN) is a niche developer of drugs against rare pathogens that avoids competing with industry behemoths. This chart on GURU.Markets shows that the separate_debt_short metric is 0.01. Its monopoly status in travel medicine, driven by a unique chikungunya vaccine, is protected by patents. In-house manufacturing plants and Lyme disease research transform Valneva SE (VALN) into a key element of the global epidemiological control system.

Short-term debt measures the total liabilities with a maturity horizon of up to twelve months, allowing for the diagnosis of liquidity risks and cash flow gaps. For Valneva SE (VALN) in the biopharmaceutical sector, this parameter is critical due to colossal R&D and clinical trial expenditures. By analyzing the history of short-term debt, an investor assesses the company's ability to fund bioengineering without external dependence. A stable level of borrowing confirms financial stability, which guarantees the preservation of the business's high-tech potential.